Oral lichen planus and intake of drugs metabolized by polymorphic cytochrome P450 enzymes
| Autor: | Carsten E. Thomsen, Allan Bardow, Birgitte Nauntofte, Anne Marie Lynge Pedersen, Camilla Kragelund, Jesper Reibel, L. A. Torpet |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Drug
Polypharmacy biology business.industry media_common.quotation_subject Case-control study Physiology Cytochrome P450 Pharmacology medicine.disease stomatognathic diseases Pharmacotherapy stomatognathic system Otorhinolaryngology Toxicity biology.protein medicine Oral lichen planus business General Dentistry Drug metabolism media_common |
| Zdroj: | Oral Diseases. 9:177-187 |
| ISSN: | 1354-523X |
| DOI: | 10.1034/j.1601-0825.2003.02892.x |
| Popis: | OBJECTIVE: To study if patients with oral lichen planus (OLP) had a medication profile different from that of a control group without oral mucosal lesions. It was hypothesized that OLP lesions might result from poor drug metabolism (PM) because of genetic variation of the major cytochrome P450-enzymes (CYPs with a PM-risk). SUBJECTS AND METHODS: Dental records of 172 OLP patients were reviewed in this cross-sectional study and 152 sex- and age-matched subjects served as controls. The measures for the drug profiles were medicine type (ATC-code), mono- and polypharmacy, CYP-enzyme metabolism pattern, and medicine with a potential to induce lichenoid drug eruptions. RESULTS: Fifty per cent of the OLP patients consumed daily medications as compared with 59% of the controls. The OLP patients more frequently consumed medicines metabolized by CYPs with a PM-risk (P = 0.03). Furthermore, they consumed more medicine with an inhibitory effect on one or more CYPs than the controls (P = 0.01). CONCLUSION: Confounders like sex, age, systemic diseases, drug distribution into the therapeutic classes, and polypharmacy were similar in the two groups; but the OLP patients consumed more drugs metabolized by CYPs with a PM-risk. The results argue for further investigation of associations between OLP, medication intake and the CYP-enzyme metabolic pathways. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text